Zenith Health Care Share Price
Sector: Biotechnology & Drugs
4.39 -0.06 (-1.35%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
4.30
Today’s High
4.59
52 Week Low
3.82
52 Week High
6.87
Key Metrics
- Market Cap (In Cr) 23.43
- Beta 0.9
- Div. Yield (%) 0
- P/B 3.19
- TTM P/E 245.88
- Sector P/E 25.02
- Open Price 4.59
- Prev Close 4.45
Zenith Health Care Analysis
Price Analysis
-
1 Week-2.23%
-
3 Months-9.3%
-
6 Month-19.89%
-
YTD-15.09%
-
1 Year-1.35%
Risk Meter
- 45% Low risk
- 45% Moderate risk
- 45% Balanced Risk
- 45% High risk
- 45% Extreme risk
Zenith Health Care News
Q4 results today: LIC, Info Edge, Minda Corp, Supriya Lifesciences, Bosch, more
2 min read . 27 May 2025Zenith Health Care Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 11.33
- Selling/ General/ Admin Expenses Total
- 1.75
- Depreciation/ Amortization
- 0.23
- Other Operating Expenses Total
- 4.07
- Total Operating Expense
- 11.47
- Operating Income
- -0.14
- Net Income Before Taxes
- 0.28
- Net Income
- 0.07
- Diluted Normalized EPS
- 0.01
- Period
- 2025
- Total Assets
- 10.88
- Total Liabilities
- 3.47
- Total Equity
- 7.41
- Tangible Book Valueper Share Common Eq
- 1.37
- Period
- 2025
- Cashfrom Operating Activities
- 0.67
- Cashfrom Investing Activities
- -1.09
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- -0.41
- Period
- 2024
- Total Revenue
- 14.47
- Selling/ General/ Admin Expenses Total
- 1.73
- Depreciation/ Amortization
- 0.21
- Other Operating Expenses Total
- 4.58
- Total Operating Expense
- 14.43
- Operating Income
- 0.04
- Net Income Before Taxes
- 0.28
- Net Income
- 0.2
- Diluted Normalized EPS
- 0.04
- Period
- 2024
- Total Assets
- 9.89
- Total Liabilities
- 2.55
- Total Equity
- 7.34
- Tangible Book Valueper Share Common Eq
- 1.37
- Period
- 2024
- Cashfrom Operating Activities
- 1.74
- Cashfrom Investing Activities
- -0.11
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- 1.63
- Period
- 2023
- Total Revenue
- 13.13
- Selling/ General/ Admin Expenses Total
- 1.55
- Depreciation/ Amortization
- 0.28
- Other Operating Expenses Total
- 3.47
- Total Operating Expense
- 13.37
- Operating Income
- -0.24
- Net Income Before Taxes
- 0.12
- Net Income
- 0.08
- Diluted Normalized EPS
- 0.01
- Period
- 2023
- Total Assets
- 9.25
- Total Liabilities
- 2.02
- Total Equity
- 7.23
- Tangible Book Valueper Share Common Eq
- 1.35
- Period
- 2023
- Cashfrom Operating Activities
- -0.95
- Cashfrom Investing Activities
- -0.03
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- -0.98
- Period
- 2022
- Total Revenue
- 22.36
- Selling/ General/ Admin Expenses Total
- 1.64
- Depreciation/ Amortization
- 0.36
- Other Operating Expenses Total
- 7.66
- Total Operating Expense
- 22.26
- Operating Income
- 0.1
- Net Income Before Taxes
- 0.61
- Net Income
- 0.31
- Diluted Normalized EPS
- 0.06
- Period
- 2022
- Total Assets
- 11.67
- Total Liabilities
- 4.51
- Total Equity
- 7.15
- Tangible Book Valueper Share Common Eq
- 1.33
- Period
- 2022
- Cashfrom Operating Activities
- 1.32
- Cashfrom Investing Activities
- -0.23
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- 1.09
- Period
- 2021
- Total Revenue
- 13.74
- Selling/ General/ Admin Expenses Total
- 1.32
- Depreciation/ Amortization
- 0.25
- Other Operating Expenses Total
- 3.73
- Total Operating Expense
- 13.52
- Operating Income
- 0.22
- Net Income Before Taxes
- 0.68
- Net Income
- 0.44
- Diluted Normalized EPS
- 0.08
- Period
- 2021
- Total Assets
- 8.77
- Total Liabilities
- 1.92
- Total Equity
- 6.84
- Tangible Book Valueper Share Common Eq
- 1.27
- Period
- 2021
- Cashfrom Operating Activities
- -1.47
- Cashfrom Investing Activities
- -0.19
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- -1.65
- Period
- 2020
- Total Revenue
- 11.98
- Selling/ General/ Admin Expenses Total
- 1.21
- Depreciation/ Amortization
- 0.25
- Other Operating Expenses Total
- 2.86
- Total Operating Expense
- 11.69
- Operating Income
- 0.29
- Net Income Before Taxes
- 0.58
- Net Income
- 0.57
- Diluted Normalized EPS
- 0.11
- Period
- 2020
- Total Assets
- 8.54
- Total Liabilities
- 2.14
- Total Equity
- 6.4
- Tangible Book Valueper Share Common Eq
- 1.19
- Period
- 2020
- Cashfrom Operating Activities
- 1.95
- Cashfrom Investing Activities
- -0.5
- Cashfrom Financing Activities
- -0.02
- Net Changein Cash
- 1.44
- Period
- 2019
- Total Revenue
- 9.83
- Selling/ General/ Admin Expenses Total
- 1.09
- Depreciation/ Amortization
- 0.25
- Other Operating Expenses Total
- 1.87
- Total Operating Expense
- 9.87
- Operating Income
- -0.04
- Net Income Before Taxes
- 0.17
- Net Income
- 0.14
- Diluted Normalized EPS
- 0.03
- Period
- 2019
- Total Assets
- 6.96
- Total Liabilities
- 1.16
- Total Equity
- 5.8
- Tangible Book Valueper Share Common Eq
- 1.08
- Period
- 2019
- Cashfrom Operating Activities
- -0.06
- Cashfrom Investing Activities
- -0.05
- Cashfrom Financing Activities
- 0.02
- Net Changein Cash
- -0.09
- Period
- 2025-03-31
- Total Revenue
- 3.43
- Selling/ General/ Admin Expenses Total
- 0.35
- Depreciation/ Amortization
- 0.08
- Other Operating Expenses Total
- 1.56
- Total Operating Expense
- 3.48
- Operating Income
- -0.06
- Net Income Before Taxes
- 0.05
- Net Income
- 0.11
- Diluted Normalized EPS
- 0.02
- Period
- 2025-03-31
- Total Assets
- 10.88
- Total Liabilities
- 3.47
- Total Equity
- 7.41
- Tangible Book Valueper Share Common Eq
- 1.37
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 0.67
- Cashfrom Investing Activities
- -1.09
- Net Changein Cash
- -0.41
- Period
- 2024-12-31
- Total Revenue
- 2.31
- Selling/ General/ Admin Expenses Total
- 0.5
- Depreciation/ Amortization
- 0.07
- Other Operating Expenses Total
- 0.82
- Total Operating Expense
- 2.57
- Operating Income
- -0.27
- Net Income Before Taxes
- -0.11
- Net Income
- -0.29
- Diluted Normalized EPS
- -0.05
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 3.03
- Selling/ General/ Admin Expenses Total
- 0.48
- Depreciation/ Amortization
- 0.04
- Other Operating Expenses Total
- 0.7
- Total Operating Expense
- 2.92
- Operating Income
- 0.1
- Net Income Before Taxes
- 0.18
- Net Income
- 0.09
- Diluted Normalized EPS
- 0.02
- Period
- 2024-09-30
- Total Assets
- 10.52
- Total Liabilities
- 2.94
- Total Equity
- 7.59
- Tangible Book Valueper Share Common Eq
- 1.41
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 0.44
- Cashfrom Investing Activities
- -0.66
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- -0.22
- Period
- 2024-06-30
- Total Revenue
- 2.57
- Selling/ General/ Admin Expenses Total
- 0.42
- Depreciation/ Amortization
- 0.04
- Other Operating Expenses Total
- 0.99
- Total Operating Expense
- 2.49
- Operating Income
- 0.08
- Net Income Before Taxes
- 0.16
- Net Income
- 0.16
- Diluted Normalized EPS
- 0.03
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 3.07
- Selling/ General/ Admin Expenses Total
- 0.48
- Depreciation/ Amortization
- 0.05
- Other Operating Expenses Total
- 1.03
- Total Operating Expense
- 3.37
- Operating Income
- -0.3
- Net Income Before Taxes
- -0.19
- Net Income
- -0.26
- Diluted Normalized EPS
- -0.05
- Period
- 2024-03-31
- Total Assets
- 9.89
- Total Liabilities
- 2.55
- Total Equity
- 7.34
- Tangible Book Valueper Share Common Eq
- 1.37
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1.74
- Cashfrom Investing Activities
- -0.11
- Cashfrom Financing Activities
- 0
- Net Changein Cash
- 1.63
- Period
- 2023-12-31
- Total Revenue
- 3.89
- Selling/ General/ Admin Expenses Total
- 0.43
- Depreciation/ Amortization
- 0.05
- Other Operating Expenses Total
- 1.31
- Total Operating Expense
- 3.85
- Operating Income
- 0.04
- Net Income Before Taxes
- 0.1
- Net Income
- 0.1
- Diluted Normalized EPS
- 0.02
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Zenith Health Care Technical
Moving Average
SMA
- 5 Day4.45
- 10 Day4.48
- 20 Day4.51
- 50 Day4.58
- 100 Day4.79
- 300 Day5.19
Zenith Health Care Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Vineet Laboratories
- 29.79
- -0.6
- -1.97
- 78.48
- 25.35
- 27.47
- Ishita Drugs And Industries
- 80.9
- 0.9
- 1.13
- 104.75
- 61.7
- 24.19
- Zenith Health Care
- 4.39
- -0.06
- -1.35
- 6.87
- 3.82
- 23.43
- Bacil Pharma
- 39.48
- 0
- 0
- 62.56
- 14.85
- 23.25
- Fone4 Communications (india)
- 8.84
- -0.46
- -4.95
- 19.25
- 3.78
- 15.08
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Vineet Laboratories
- -
- 1.89
- -6.99
- -1.09
- Ishita Drugs And Industries
- 27.9
- 2.24
- 8.63
- 5.45
- Zenith Health Care
- 337.69
- 3.19
- 3.1
- 1.46
- Bacil Pharma
- 61.69
- 2.17
- -21.03
- -
- Fone4 Communications (india)
- -
- 3.84
- -
- -
Zenith Health Care Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 27-May-25
- Audited Results
- 11-Feb-25
- Quarterly Results
- 24-Oct-24
- Quarterly Results
- 01-Aug-24
- Others
- 20-Jul-24
- Quarterly Results
- 29-May-24
- Audited Results
- 12-Feb-24
- Quarterly Results
- 06-Nov-23
- Quarterly Results
- 12-Aug-23
- Quarterly Results
- 10-Jul-23
- Others
- Meeting Date
- Announced on
- Purpose
- 26-Aug-24
- 01-Aug-24
- AGM
- 26-Sept-23
- 31-Aug-23
- AGM



